Drugs.com - New Drug Approvals

FDA Approves Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) Subcutaneous Injection for Use in Most Previously Approved Solid Tumor Opdivo (nivolumab) Indications

PRINCETON, N.J.--(BUSINESS WIRE) December 27, 2024 -- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) granted approval for Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for...

Feb 9, 2025 - 21:45
 0
FDA Approves Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) Subcutaneous Injection for Use in Most Previously Approved Solid Tumor Opdivo (nivolumab) Indications
PRINCETON, N.J.--(BUSINESS WIRE) December 27, 2024 -- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) granted approval for Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for...
Read More

Tags:

Previous Article

FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treat...

Next Article

Vertex Announces U.S. FDA Approval for Trikafta (elexacaftor/tezacaftor/ivacafto...

Related Posts

U.S. FDA Grants Full Approval of Vitrakvi (larotrectinib) for Adult and Pediatric Patients with NTRK Gene Fusion-Positive Solid Tumors

U.S. FDA Grants Full Approval of Vitrakvi (larotrectini...

Apr 14, 2025  0

FDA Approves Odactra for the Treatment of House Dust Mite Allergy in Young Children

FDA Approves Odactra for the Treatment of House Dust Mi...

Mar 1, 2025  0

Calquence Plus Chemoimmunotherapy Approved in the U.S. for Patients with Previously Untreated Mantle Cell Lymphoma

Calquence Plus Chemoimmunotherapy Approved in the U.S. ...

Feb 9, 2025  0